Annovis Bio to Present Multi-Protein Alzheimer's Approach at Fierce Biotech Week

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, is set to present at Fierce Biotech Week 2026 in Boston on May 13. President and CEO Maria Maccecchini, Ph.D., will discuss the scientific basis for treating Alzheimer’s disease as a multi-protein disorder, highlighting the company’s innovative approach with its lead drug candidate, buntanetap. Unlike traditional therapies that target a single protein, buntanetap simultaneously inhibits multiple neurotoxic proteins—including APP, amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism. This multi-pronged strategy aims to address the underlying causes of neurodegeneration, potentially halting disease progression and improving cognitive and motor functions in patients with Alzheimer’s and Parkinson’s diseases. The presentation underscores Annovis’ commitment to advancing its pivotal Phase 3 clinical trial for buntanetap, which represents a novel therapeutic approach in the neurodegenerative disease landscape.

Headquartered in Malvern, Pennsylvania, Annovis Bio is at the forefront of developing treatments for Alzheimer’s disease (AD) and Parkinson’s disease (PD). The company’s focus on buntanetap (formerly posiphen) as an investigational once-daily oral therapy sets it apart in the biotech sector. By targeting the translation of multiple neurotoxic proteins, Annovis aims to overcome the limitations of single-target drugs that have historically failed to modify disease progression. The presentation at Fierce Biotech Week provides a platform for Maccecchini to share insights on the scientific rationale behind this approach and the potential impact on patients. For more details, the full press release is available at https://ibn.fm/kZ2Z4. The company also maintains a newsroom at https://ibn.fm/ANVS for the latest updates.

Annovis Bio is part of a broader ecosystem supported by MissionIR, a specialized communications platform under the Dynamic Brand Portfolio @ IBN. MissionIR assists IR firms with syndicated content, leveraging a vast network of wire solutions via InvestorWire and editorial syndication to 5,000+ outlets. This infrastructure helps companies like Annovis gain visibility among investors, influencers, and the general public. The upcoming presentation by Annovis at Fierce Biotech Week is a key event that could shape investor sentiment and highlight the potential of multi-protein targeting in neurodegenerative diseases. As buntanetap progresses through clinical trials, the biotech community will be closely watching for data that could validate this novel therapeutic strategy.